Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography.


Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 09 10 2020
accepted: 13 01 2021
pubmed: 28 1 2021
medline: 17 11 2021
entrez: 27 1 2021
Statut: ppublish

Résumé

This study aimed to test the diagnostic significance of FET-PET imaging combined with machine learning for the differentiation between multiple sclerosis (MS) and glioma II°-IV°. Our database was screened for patients in whom FET-PET imaging was performed for the diagnostic workup of newly diagnosed lesions evident on MRI and suggestive of glioma. Among those, we identified patients with histologically confirmed glioma II°-IV°, and those who later turned out to have MS. For each group, tumor-to-brain ratio (TBR) derived features of FET were determined. A support vector machine (SVM) based machine learning algorithm was constructed to enhance classification ability, and Receiver Operating Characteristic (ROC) analysis with area under the curve (AUC) metric served to ascertain model performance. A total of 41 patients met selection criteria, including seven patients with MS and 34 patients with glioma. TBR values were significantly higher in the glioma group (TBRmax glioma vs. MS: p = 0.002; TBRmean glioma vs. MS: p = 0.014). In a subgroup analysis, TBR values significantly differentiated between MS and glioblastoma (TBRmax glioblastoma vs. MS: p = 0.0003, TBRmean glioblastoma vs. MS: p = 0.0003) and between MS and oligodendroglioma (ODG) (TBRmax ODG vs. MS: p = 0.003; TBRmean ODG vs. MS: p = 0.01). The ability to differentiate between MS and glioma II°-IV° increased from 0.79 using standard TBR analysis to 0.94 using a SVM based machine learning algorithm. FET-PET imaging may help differentiate MS from glioma II°-IV° and SVM based machine learning approaches can enhance classification performance.

Identifiants

pubmed: 33502678
doi: 10.1007/s11060-021-03701-1
pii: 10.1007/s11060-021-03701-1
doi:

Substances chimiques

Radiopharmaceuticals 0
(18F)fluoroethyltyrosine 1326R5J1IA
Tyrosine 42HK56048U

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

325-332

Références

Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ (2014) Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 83:1022–1024. https://doi.org/10.1212/wnl.0000000000000768
doi: 10.1212/wnl.0000000000000768 pubmed: 25200713 pmcid: 4162299
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintore M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173. https://doi.org/10.1016/s1474-4422(17)30470-2
doi: 10.1016/s1474-4422(17)30470-2 pubmed: 29275977
Hardy TA (2019) Pseudotumoral demyelinating lesions: diagnostic approach and long-term outcome. Curr Opin Neurol 32:467–474. https://doi.org/10.1097/wco.0000000000000683
doi: 10.1097/wco.0000000000000683 pubmed: 30844860
Jakola AS, Skjulsvik AJ, Myrmel KS, Sjavik K, Unsgard G, Torp SH, Aaberg K, Berg T, Dai HY, Johnsen K, Kloster R, Solheim O (2017) Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol 28:1942–1948. https://doi.org/10.1093/annonc/mdx230
doi: 10.1093/annonc/mdx230 pubmed: 28475680 pmcid: 5834105
Hayashi T, Kumabe T, Jokura H, Fujihara K, Shiga Y, Watanabe M, Higano S, Shirane R (2003) Inflammatory demyelinating disease mimicking malignant glioma. J Nucl Med 44:565–569
pubmed: 12679401
Kebir S, Gaertner FC, Mueller M, Nelles M, Simon M, Schafer N, Stuplich M, Schaub C, Niessen M, Mack F, Bundschuh R, Greschus S, Essler M, Glas M, Herrlinger U (2016) (18)F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: a case report. Oncol Lett 11:2195–2198. https://doi.org/10.3892/ol.2016.4189
doi: 10.3892/ol.2016.4189 pubmed: 26998148 pmcid: 4774557
Pakos EE, Tsekeris PG, Chatzidimou K, Goussia AC, Markoula S, Argyropoulou MI, Pitouli EG, Konitsiotis S (2005) Astrocytoma-like multiple sclerosis. Clin Neurol Neurosurg 107:152–157. https://doi.org/10.1016/j.clineuro.2004.06.003
doi: 10.1016/j.clineuro.2004.06.003 pubmed: 15708234
Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P, Zephir H, Duhin E, Gout O, Deschamps R, Le Page E, Edan G, Labauge P, Carra-Dallieres C, Rumbach L, Berger E, Lejeune P, Devos P, N’Kendjuo JB, Coustans M, Auffray-Calvier E, Daumas-Duport B, Michel L, Lefrere F, Laplaud DA, Brosset C, Derkinderen P, de Seze J, Wiertlewski S, Francophone S (2018) Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. J Neurol 265:2251–2259. https://doi.org/10.1007/s00415-018-8984-7
doi: 10.1007/s00415-018-8984-7 pubmed: 30054790
Kim DS, Na DG, Kim KH, Kim JH, Kim E, Yun BL, Chang KH (2009) Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology 251:467–475. https://doi.org/10.1148/radiol.2512072071
doi: 10.1148/radiol.2512072071 pubmed: 19261924
Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, la Fougere C, Langen KJ, Lopci E, Lowe V, McConathy J, Quick HH, Sattler B, Schuster DM, Tonn JC, Weller M (2019) Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18) F] FDG: version 1.0. Eur J Nucl Med Mol Imaging 46:540–557. https://doi.org/10.1007/s00259-018-4207-9
doi: 10.1007/s00259-018-4207-9 pubmed: 30519867
Pauleit D, Floeth F, Herzog H, Hamacher K, Tellmann L, Muller HW, Coenen HH, Langen KJ (2003) Whole-body distribution and dosimetry of O-(2-[18F] fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imaging 30:519–524. https://doi.org/10.1007/s00259-003-1118-0
doi: 10.1007/s00259-003-1118-0 pubmed: 12589478
Pauleit D, Zimmermann A, Stoffels G, Bauer D, Risse J, Fluss MO, Hamacher K, Coenen HH, Langen KJ (2006) 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med 47:256–261
pubmed: 16455631
Rau FC, Weber WA, Wester HJ, Herz M, Becker I, Kruger A, Schwaiger M, Senekowitsch-Schmidtke R (2002) O-(2-[(18) F] Fluoroethyl) - L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging 29:1039–1046. https://doi.org/10.1007/s00259-002-0821-6
doi: 10.1007/s00259-002-0821-6 pubmed: 12173018
Chang CH, Wang HE, Wu SY, Fan KH, Tsai TH, Lee TW, Chang SR, Liu RS, Chen CF, Chen CH, Fu YK (2006) Comparative evaluation of FET and FDG for differentiating lung carcinoma from inflammation in mice. Anticancer Res 26:917–925
pubmed: 16619487
Barbagallo M, Albatly AA, Schreiner S, Hayward-Konnecke HK, Buck A, Kollias SS, Huellner MW (2018) Value of 18F-FET PET in patients with suspected tumefactive demyelinating disease-preliminary experience from a retrospective analysis. Clin Nucl Med 43:e385–e391. https://doi.org/10.1097/rlu.0000000000002244
doi: 10.1097/rlu.0000000000002244 pubmed: 30153143
Floeth FW, Pauleit D, Sabel M, Reifenberger G, Stoffels G, Stummer W, Rommel F, Hamacher K, Langen KJ (2006) 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 47:776–782
pubmed: 16644747
Pichler R, Dunzinger A, Wurm G, Pichler J, Weis S, Nussbaumer K, Topakian R, Aigner RM (2010) Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging 37:1521–1528. https://doi.org/10.1007/s00259-010-1457-6
doi: 10.1007/s00259-010-1457-6 pubmed: 20396883
Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, Sabel M, Steiger HJ, Reifenberger G, Beez T, Coenen HH, Floeth FW, Langen KJ (2013) Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med 54:229–235. https://doi.org/10.2967/jnumed.112.109603
doi: 10.2967/jnumed.112.109603 pubmed: 23232275
Hashimoto S, Inaji M, Nariai T, Kobayashi D, Sanjo N, Yokota T, Ishii K, Taketoshi M (2019) Usefulness of [(11) C] methionine PET in the differentiation of tumefactive multiple sclerosis from high grade astrocytoma. Neurol Med Chir 59:176–183. https://doi.org/10.2176/nmc.oa.2018-0287
doi: 10.2176/nmc.oa.2018-0287
Topol EJ (2019) High-performance medicine: the convergence of human and artificial intelligence. Nat Med 25:44–56. https://doi.org/10.1038/s41591-018-0300-7
doi: 10.1038/s41591-018-0300-7 pubmed: 30617339
Kebir S, Lazaridis L, Weber M, Deuschl C, Stoppek AK, Schmidt T, Monninghoff C, Blau T, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Stuschke M, Antoch G, Sure U, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Herrmann K, Glas M (2019) Comparison of L-Methyl-11C-methionine PET with magnetic resonance spectroscopy in detecting newly diagnosed glioma. Clin Nucl Med 44:e375–e381. https://doi.org/10.1097/rlu.0000000000002577
doi: 10.1097/rlu.0000000000002577 pubmed: 30985412
Kebir S, Weber M, Lazaridis L, Deuschl C, Schmidt T, Monninghoff C, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Sure U, Stuschke M, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Rischpler C, Glas M (2019) Hybrid 11C-MET PET/MRI combined with “machine learning” in glioma diagnosis according to the revised glioma WHO classification 2016. Clin Nucl Med 44:214–220. https://doi.org/10.1097/rlu.0000000000002398
doi: 10.1097/rlu.0000000000002398 pubmed: 30516675
Vallieres M, Kay-Rivest E, Perrin LJ, Liem X, Furstoss C, Aerts H, Khaouam N, Nguyen-Tan PF, Wang CS, Sultanem K, Seuntjens J, El Naqa I (2017) Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. Sci Rep 7:10117. https://doi.org/10.1038/s41598-017-10371-5
doi: 10.1038/s41598-017-10371-5 pubmed: 28860628 pmcid: 5579274
Wiyaporn K, Tocharoenchai C, Pusuwan P, Ekjeen T, Leaungwutiwong S, Thanyarak S (2010) Factors affecting standardized uptake value (SUV) of positron emission tomography (PET) imaging with l8F-FDG. J Med Assoc Thai 93:108–114
pubmed: 20196419
Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Fürst S, Martinez-Möller A, Nekolla SG, Ziegler S, Ganter C, Rummeny EJ, Schwaiger M (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53:845–855. https://doi.org/10.2967/jnumed.111.098608
doi: 10.2967/jnumed.111.098608 pubmed: 22534830
Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, Pfannenberg C, Pichler BJ, Reimold M, Stegger L (2010) Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med 51:1198–1205. https://doi.org/10.2967/jnumed.110.074773
doi: 10.2967/jnumed.110.074773
Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, Czernin J, Kessler AF, Homola GA, Ernestus RI, Lohr M, Herrmann K (2014) Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med 55:1611–1616. https://doi.org/10.2967/jnumed.114.140608
doi: 10.2967/jnumed.114.140608 pubmed: 25125481
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
doi: 10.1007/s00401-016-1545-1
Huang S, Cai N, Pacheco PP, Narrandes S, Wang Y, Xu W (2018) Applications of support vector machine (SVM) learning in cancer genomics. Cancer Genomics Proteomics 15:41–51. https://doi.org/10.21873/cgp.20063
doi: 10.21873/cgp.20063 pubmed: 29275361
Jordan MI, Mitchell TM (2015) Machine learning: trends, perspectives, and prospects. Science 349:255–260. https://doi.org/10.1126/science.aaa8415
doi: 10.1126/science.aaa8415 pubmed: 26185243
Smits A, Baumert BG (2011) The clinical value of PET with amino acid tracers for gliomas WHO grade II. Int J Mol Imaging 2011:372509. https://doi.org/10.1155/2011/372509
doi: 10.1155/2011/372509 pubmed: 21603237 pmcid: 3094834
Glotsos D, Spyridonos P, Cavouras D, Ravazoula P, Dadioti PA, Nikiforidis G (2005) An image-analysis system based on support vector machines for automatic grade diagnosis of brain-tumour astrocytomas in clinical routine. Med Inform Internet Med 30:179–193. https://doi.org/10.1080/14639230500077444
doi: 10.1080/14639230500077444 pubmed: 16403707
Filss CP, Albert NL, Böning G, Kops ER, Suchorska B, Stoffels G, Galldiks N, Shah NJ, Mottaghy FM, Bartenstein P, Tonn JC, Langen KJ (2017) O-(2-[(18) F] fluoroethyl)-L-tyrosine PET in gliomas: influence of data processing in different centres. EJNMMI Res 7:64. https://doi.org/10.1186/s13550-017-0316-x
doi: 10.1186/s13550-017-0316-x pubmed: 28815478 pmcid: 5559408
Cunliffe CH, Fischer I, Monoky D, Law M, Revercomb C, Elrich S, Kopp MJ, Zagzag D (2009) Intracranial lesions mimicking neoplasms. Arch Pathol Lab Med 133:101–123. https://doi.org/10.1043/1543-2165-133.1.101
doi: 10.1043/1543-2165-133.1.101 pubmed: 19123722

Auteurs

Sied Kebir (S)

Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
West German Cancer Center (WTZ), German Cancer Consortium (DKTK), University Hospital Essen, University Duisburg-Essen, Partner Site University Hospital Essen, Essen, Germany.
DKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Laurèl Rauschenbach (L)

DKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
Department of Neurosurgery and Spine Surgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Manuel Weber (M)

Department of Nuclear Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Lazaros Lazaridis (L)

Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
West German Cancer Center (WTZ), German Cancer Consortium (DKTK), University Hospital Essen, University Duisburg-Essen, Partner Site University Hospital Essen, Essen, Germany.
DKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Teresa Schmidt (T)

Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
West German Cancer Center (WTZ), German Cancer Consortium (DKTK), University Hospital Essen, University Duisburg-Essen, Partner Site University Hospital Essen, Essen, Germany.

Kathy Keyvani (K)

Institute of Neuropathology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Niklas Schäfer (N)

Division of Clinical Neurooncology, Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany.

Asma Milia (A)

Department of Pulmonology and Cardiology, Petrus Hospital Academic Teaching, Wuppertal, Germany.

Lale Umutlu (L)

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Daniela Pierscianek (D)

Department of Neurosurgery and Spine Surgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Martin Stuschke (M)

Department of Radiotherapy, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Michael Forsting (M)

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Ulrich Sure (U)

Department of Neurosurgery and Spine Surgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Christoph Kleinschnitz (C)

Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Gerald Antoch (G)

Department of Diagnostic and Interventional Radiology, University Hospital Düsseldorf, University of Düsseldorf, Düsseldorf, Germany.

Patrick M Colletti (PM)

Department of Radiology, University of Southern California, Los Angeles, USA.

Domenico Rubello (D)

Department of Nuclear Medicine, Radiology, Neuroradiology, Clinical Pathology, S. Maria Della Misericordia Hospital, Rovigo, Italy.

Ken Herrmann (K)

Department of Nuclear Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Ulrich Herrlinger (U)

Division of Clinical Neurooncology, Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany.

Björn Scheffler (B)

West German Cancer Center (WTZ), German Cancer Consortium (DKTK), University Hospital Essen, University Duisburg-Essen, Partner Site University Hospital Essen, Essen, Germany.
DKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Ralph A Bundschuh (RA)

Department of Nuclear Medicine, University Hospital Bonn, University of Bonn, Bonn, Germany.

Martin Glas (M)

Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. martin.glas@uk-essen.de.
West German Cancer Center (WTZ), German Cancer Consortium (DKTK), University Hospital Essen, University Duisburg-Essen, Partner Site University Hospital Essen, Essen, Germany. martin.glas@uk-essen.de.
DKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany. martin.glas@uk-essen.de.
Division of Clinical Neurooncology, Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany. martin.glas@uk-essen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH